International oncology treatment programs featuring Cuba's CIMAvax-EGF and Vaxira immunotherapies, combined with integrative cancer care and comprehensive supportive services for U.S. patients and families.
La Pradera International Health Center offers an international oncology treatment program that combines Cuba's CIMAvax-EGF and Vaxira immunotherapies with integrative cancer care, medical supervision, and comprehensive supportive services. The program is designed for international patients seeking additional treatment options alongside their existing cancer care. Each treatment plan is personalized following a comprehensive medical records review and on-site assessment. We encourage patients to discuss all treatment options with their home-country oncologist and consider international programs as part of a comprehensive care strategy.
A Cuban-developed therapeutic vaccine designed to target the epidermal growth factor (EGF) pathway in certain cancers, primarily non-small cell lung cancer.
A Cuban-developed therapeutic vaccine designed to induce an immune response against certain cancer cells, used as a complementary approach in oncology care.
Comprehensive supportive care including nutritional support, pain management, and rehabilitation services.
Ongoing oncology evaluation and treatment monitoring by specialized physicians throughout the program.
Submit medical records including pathology reports, imaging, and treatment history for review by the oncology team.
Comprehensive oncology evaluation upon arrival to confirm eligibility and personalize the treatment plan.
Multi-week treatment program combining immunotherapy, supportive care, and rehabilitation under medical supervision.
Post-program guidance and coordination with the patient's home-country oncologist for continued care.
Select your state for localized information, travel routes, and state-specific resources for treatment in Cuba.
Cuba offers CIMAvax-EGF and Vaxira (Racotumomab), Cuban-developed therapeutic cancer vaccines, combined with integrative cancer care, medical supervision, and supportive services at La Pradera International Health Center.
CIMAvax-EGF is a Cuban-developed therapeutic vaccine designed to target the epidermal growth factor (EGF) pathway. It has been studied primarily in non-small cell lung cancer. We encourage patients to discuss this option with their home-country oncologist.
No. CIMAvax-EGF is a therapeutic vaccine designed to support the immune system's response to cancer. It is not a cure. We use non-promissory language and encourage patients to discuss all treatment options with their oncologist.
Programs typically range from 2 to 4 weeks depending on the patient's condition, treatment plan, and individual needs. The exact duration is determined after medical records review and on-site assessment.
Do not discontinue any current treatment without consulting your oncologist. The Cuban program can be complementary to your existing care. Post-program follow-up coordination with your U.S. oncologist is included.
Contact our international patient services team to discuss treatment options in Cuba for you or your loved one.
Deneyiminizi iyileştirmek ve trafiği analiz etmek için çerezler kullanıyoruz. Devam ederek çerez kullanımımızı kabul etmiş olursunuz. Gizlilik Politikası